Sword Bio positions itself as a dynamic player in the bioanalytical CRO landscape, offering rapid and customized lab services to biotech and pharmaceutical industries. Their slogan, "Rapid, Customized, and Collaborative Bioanalytical Lab Services. Your project. Your timeline," underscores their commitment to speed and flexibility.
With over 30 years of industry experience, Sword Bio excels in developing, qualifying, and validating PK, Biomarkers, and immunogenicity assays. They operate in both GLP and Non-GLP settings, demonstrating a versatile approach to meeting various client needs.
Anchored in the US, Sword Bio emphasizes a client-centric, collaborative business model, aiming to swiftly deliver essential drugs to the market. While the company currently lacks explicit founding information and recorded investment, its specialized services and expert team offer significant value to potential investors in the Biopharma, Biotechnology, and Pharmaceutical sectors. With no recent external funding, investor engagement could unlock further growth opportunities.